James Pilcher, MD
Internal Medicine · Louisville, GANPI 1942230107
Payments from drug & device makers
Across 155 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$461
- Teva Pharmaceuticals USA, Inc.$313
- Novo Nordisk$310
- GSK$296
- Biohaven Pharmaceutical Holding Company Ltd.$144
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,241100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $1,131 |
| Bayer | 18 | $461 |
| Teva Pharmaceuticals USA, Inc. | 3 | $313 |
| Novo Nordisk | 20 | $310 |
| GSK | 9 | $296 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $144 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Novartis | 8 | $132 |
| Eisai Inc. | 1 | $125 |
| UCB, Inc. | 1 | $125 |
| Johnson & Johnson | 4 | $124 |
| AbbVie(2 entities) | 3 | $117 |
| Boehringer Ingelheim | 7 | $110 |
| Otsuka America Pharmaceutical, Inc. | 1 | $98 |
| Amgen | 6 | $95 |
| Neurocrine Biosciences, Inc. | 1 | $95 |
| Pfizer | 5 | $67 |
| Lundbeck LLC | 3 | $57 |
| Lilly USA, LLC | 3 | $52 |
| Abbott | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Merck | 3 | $35 |
| Dexcom, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$132
- ELIQUIS$125
- Leqembi$125
- Zilbrysq$125
- AIRSUPRA$118
- Austedo XR$112
- NURTEC ODT$111
- AREXVY$110
- Kerendia$107
- AUSTEDO$102
How this compares
$4,253 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 259 | $216,544 |
| EliquisApixaban | 179 | $148,673 |
| OzempicSemaglutide | 64 | $103,191 |
| FarxigaDapagliflozin Propanediol | 95 | $92,751 |
| Nurtec OdtRimegepant Sulfate | 15 | $25,639 |
| LinzessLinaclotide | 27 | $21,349 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,693 |
| KerendiaFinerenone | 15 | $14,297 |
| EntrestoSacubitril/Valsartan | 18 | $14,109 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,345 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $10,877 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,340 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $3,966 |
| Gabapentin | 194 | $3,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $110 | $227,421272 claims |
| PfizerEliquis, Nurtec Odt | $67 | $174,312194 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,131 | $110,704123 claims |
| Novo NordiskOzempic | $310 | $103,19164 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $296 | $27,03838 claims |
| AbbVieLinzess | $117 | $21,34927 claims |
| BayerKerendia | $461 | $14,29715 claims |
| NovartisEntresto | $132 | $14,10918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Louisville
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.